|
?:abstract
|
-
The probability of formation of the so-called “cytokine storm” accompanied by an avalanche-like growth of inflammatory markers - interleukins (IL)-1β, -6, interferon-γ, tumor necrosis factor-α, C-reactive protein (CRP), ferritin, etc is high at a heavy current of COVID-19 In the absence of adequate treatment in the development of “cytokine storm” increases the risk of death, especially against the background of comorbid pathology Methods In April-May 2020, patients (n = 28: 12 men, 16 women;age 39 - 86 years) with long, chronic COVID-19 course were under observation, hospitalized on critical days of the disease All patients reported anosmia, cough with poor sputum, signs of conjunctivitis The patients had chronic diseases (n = 22: coronary heart disease, diabetes mellitus type 2, scleroderma) All patients were given standard therapy;half (n = 14) were additionally prescribed Laennec for 3 - 10 days (6 ml per 350 ml of 0 9% NaCl solution, intravenous infusion for the first 3 days, from day 4 - 6 ml per 250 ml of 0 9% NaCl solution) until stable remission is achieved Results The majority state (n = 25) stabilized;several patients died in the control group (n = 3;p = 0 067) In spite of the state stabilization, no reliable positive dynamics was noted in the control group for the tested parameters Initially, liver dysfunction (level of alanine aminotransferase (ALT) - 113 ± 121, aspartate aminotransferase (AST) - 90 8 ± 87) was registered in 71% of patients, 8 units/l) and high risk of “cytokine storm” development (ferritin levels in men - 480 - 1 072 µg/l, in women - 274 7 - 493 µg/l, C-reactive protein - 5 0 - 52 6 mg/l, lymphocytes - < 25%) Positive clinical dynamics, a decrease in the level of ferritin (-282 µg/l - in men, -80 µg/l - in women;p = 0 039), an increase in blood oxygenation to normal values (p = 0 0029), a decrease in the area of lung injury according to CT data (on average - 10%);p = 0 0027), increase in relative lymphocyte content (+8%;p = 0 04), normalization of markers of liver dysfunction (AST, ALT), creatinine and systolic blood pressure (p < 0 05) were observed on prescription of Laennec All patients who received Laennec recovered within 3 - 15 days from the start of the drug and were discharged with a negative test for SARS-CoV-2 Conclusion Health condition is significantly improved, a wide range of hepatoprotective, immunomodulatory and regenerative effects are observed when the polypeptide Laennec is included in the complex therapy in patients with severe COVID-19 Laennec should be used primarily in patients with liver pathology, diabetes mellitus type 2, coronary heart disease, including high ferritin levels © 2020 Medical Education All rights reserved
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}